Amendments to the claims

Listing of claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A compound selected from compounds of formula (I):



(I)

and pharmaceutically acceptable salts thereof; wherein:

one of Z_1, Z_2, Z_3, Z_4 and Z_5 is N, one is CR^{1a} and the remainder are CH, or

one or two of Z_1, Z_2, Z_3, Z_4 and Z_5 are independently CR^{1a} and the remainder are CH;

R^1 and R^{1a} are independently hydrogen; hydroxy; (C_{1-6})alkoxy unsubstituted or substituted by (C_{1-6})alkoxy, amino, piperidyl, guanidino or amidino any of which is optionally N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups, $CONH_2$, hydroxy, (C_{1-6})alkylthio, heterocyclylthio, heterocyclyloxy, arylthio, aryloxy, acylthio, acyloxy or (C_{1-6})alkylsulphonyloxy; (C_{1-6})alkoxy-substituted(C_{1-6})alkyl; halogen; (C_{1-6})alkyl; (C_{1-6})alkylthio; trifluoromethyl; trifluoromethoxy; nitro; cyano; azido; acyl; acyloxy; acylthio; (C_{1-6})alkylsulphonyl; (C_{1-6})alkylsulphoxide; arylsulphonyl; arylsulphoxide or an amino, piperidyl, guanidino or amidino group optionally N-substituted by one or two (C_{1-6})alkyl, acyl or (C_{1-6})alkylsulphonyl groups; provided that when Z_1, Z_2, Z_3, Z_4 and Z_5 are CR^{1a} or CH, then R^1 is not hydrogen;

W_1, W_2, W_3 and W_4 are each independently selected from N or CR^3;

each R^3 is independently selected from:
hydrogen; hydroxy; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di-(C_{1-6})alkylamino; and substituted and unsubstituted (C_{1-6})alkoxy, (C_{1-6})alkyl, (C_{3-7})cycloalkyl, aminocarbonyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulphonyl, and (C_{1-6})alkylsulphoxide;

A is $(CRR)_n$;

B is $(CRR)_m$, C=O, or SO_2;

n is 1 or 2;

m is 1 or 2;

provided that when n is 1, m is 2; when n is 2, m is 1; and when B is C=O or SO_2 then n is 2;

each R is independently selected from
hydrogen; halogen; trifluoromethyl; trifluoromethoxy; cyano; nitro; azido; acyl; acyloxy; acylthio; amino, mono- and di-(C_{1-6})alkylamino; and substituted and unsubstituted (C_{1-6})alkoxy, (C_{1-6})alkyl, (C_{3-7})cycloalkyl, aminocarbonyl, (C_{1-6})alkylthio, (C_{1-6})alkylsulphonyl, and (C_{1-6})alkylsulphoxide;

R^2 is a group:





~~; and~~

each R^4 and R^5 is independently selected from: hydrogen; (C_{1-4})alkylthio; halo; carboxy(C_{1-4})alkyl; halo(C_{1-4})alkoxy; halo(C_{1-4})alkyl; (C_{1-4})alkyl; (C_{1-4})alkoxycarbonyl; formyl; (C_{1-4})alkylcarbonyl; (C_{2-4})alkenyloxycarbonyl; (C_{2-4})alkenylcarbonyl; (C_{1-4})alkylcarbonyloxy; (C_{1-4})alkoxycarbonyl(C_{1-4})alkyl; hydroxy; hydroxy(C_{1-4})alkyl; mercapto(C_{1-4})alkyl; (C_{1-4})alkoxy; nitro; cyano; carboxy; amino or aminocarbonyl optionally substituted by (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl, (C_{1-4})alkyl or (C_{2-4})alkenyl and optionally further substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; (C_{2-6})alkenyl; (C_{1-4})alkylsulphonyl; (C_{2-4})alkenylsulphonyl; aminosulphonyl wherein the amino group is optionally mono- or di-substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; aryl; aryl(C_{1-4})alkyl; and aryl(C_{1-4})alkoxy; or R^4 and R^5 may together represent oxo;

R^6 is hydrogen; trifluoromethyl; (C_{1-4})alkyl unsubstituted or substituted by hydroxy, (C_{1-6})alkoxy, (C_{1-6})alkylthio, halo or trifluoromethyl; (C_{2-4})alkenyl; aryl; aryl(C_{1-4})alkyl; arylcarbonyl; heteroarylcarbonyl; (C_{1-4})alkoxycarbonyl; (C_{1-4})alkylcarbonyl; formyl; (C_{1-6})alkylsulphonyl; or aminocarbonyl wherein the amino group is optionally substituted by (C_{1-4})alkoxycarbonyl, (C_{1-4})alkylcarbonyl, (C_{2-4})alkenyloxycarbonyl, (C_{2-4})alkenylcarbonyl, (C_{1-4})alkyl or (C_{2-4})alkenyl and optionally further substituted by (C_{1-4})alkyl or (C_{2-4})alkenyl; and

~~wherein the term acyl means a formyl or a (C_{1-6})alkylcarbonyl group;~~
"acyl" is a formyl or a (C_{1-6})alkylcarbonyl group.

~~or a pharmaceutically acceptable salt thereof.~~

Claims 2-21 (Canceled).

22. (New) The compound according to claim 1 wherein Z_5 is CH or N, Z_3 is CH or CF and Z_1, Z_2 and Z_4 are each CH, or Z_1 is N, Z_3 is CH or CF and Z_2, Z_4 and Z_5 are each CH.

23. (New) The compound according to claim 1 wherein R^1 is methoxy and R^{1a} is H or when Z_3 is CR^{1a} it may be C-F.

24. (New) The compound according to claim 1 wherein:

a) W_1-W_4 are independently CR^3;

b) W_1, W_3 and W_4 are N and W_2 is CR^3;

c) W_2 is N and W_1, W_3 and W_4 are independently CR^3;

d) W_3 is N and W_1, W_2 and W_4 are independently CR^3; or

e) W_4 is N and W_1-W_3 are independently CR^3.

25. (New) The compound according to claim 1 wherein R^3 is independently selected from hydrogen, substituted and unsubstituted (C_{1-6})alkoxy, and NH_2.

26. (New) The compound according to claim 1 wherein R is independently selected from hydrogen, substituted and unsubstituted (C_{1-6})alkyl, $CONH_2$, COOH, hydroxy, halogen, and substituted and unsubstituted (C_{1-6})alkoxy.

27. (New) The compound according to claim 1 wherein R^4 and R^5 are independently selected from hydrogen, halo, hydroxy, (C_{1-4})alkoxy, trifluoromethoxy, nitro, cyano, aryl(C_{1-4})alkoxy and (C_{1-4})alkylsulphonyl, and R^6 is H or (C_{1-4})alkyl.

28. (New) The compound according to claim 27 wherein each R^4 is independently selected from hydrogen, chloro, fluoro, hydroxy, methoxy, trifluoromethoxy, benzyloxy, nitro, cyano and methylsulphonyl, and R^5 and R^6 are hydrogen.

29. (New) The compound according to claim 28 wherein R^4 is independently hydrogen, fluorine or nitro.

30. (New) The compound according to claim 29 wherein R^4 is hydrogen.

31. (New) The compound according to claim 1 wherein R^2 is a group:



32. (New) The compound according to claim 31 wherein R^4 and R^5 are independently selected from hydrogen, halo, hydroxy, (C_{1-4})alkoxy, trifluoromethoxy, nitro, cyano, aryl(C_{1-4})alkoxy and (C_{1-4})alkylsulphonyl, and R^6 is H or (C_{1-4})alkyl.

33. (New) The compound according to claim 32 wherein each R^4 is independently selected from hydrogen, chloro, fluoro, hydroxy, methoxy, trifluoromethoxy, benzyloxy, nitro, cyano and methylsulphonyl, and R^5 and R^6 are hydrogen.

34. (New) The compound according to claim 33 wherein R^4 is independently hydrogen, fluorine or nitro.

35. (New) The compound according to claim 34 wherein R^4 is hydrogen.

36. (New) A compound selected from the following compounds and pharmaceutically acceptable salts thereof:

6-({2-[4-(6-Methoxy-[1,5]naphthyridin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({2-[4-(6,8-difluoroquinolin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({2-[4-(8-Fluoro-6-methoxyquinolin-4-yl)phenyl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({2-[6-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-3-yl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

6-({2-[5-(6-methoxy-[1,5]naphthyridin-4-yl)pyridin-2-yl]ethylamino}methyl)-4*H*-pyrido[3,2-*b*][1,4]thiazin-3-one;

N-(2-{6-[6-(methyloxy)-1,5-naphthyridin-4-yl]-3-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide;

N-(2-{5-[6-(methyloxy)-1,5-naphthyridin-4-yl]-2-pyridinyl}ethyl)-3-oxo-3,4-dihydro-2*H*-pyrido[3,2-*b*][1,4]thiazine-6-carboxamide.

37. (New) The compound according to claim 1 wherein:

Z_5 is CH or N, Z_3 is CH or CF and Z_1, Z_2 and Z_4 are each CH; or

Z_1 is N, Z_3 is CH or CF and Z_2, Z_4 and Z_5 are each CH;

R^1 is methoxy, amino(C_{3-5})alkyloxy, guanidino(C_{3-5})alkyloxy, piperidyl(C_{3-5})alkyloxy, nitro or fluoro;

W_1-W_4 are independently CR^3; or

W_1, W_3 and W_4 are N and W_2 is CR^3; or

W_2 is N and W_1, W_3 and W_4 are independently CR^3; or

W_3 is N and W_1, W_2 and W_4 are independently CR^3; or

W_4 is N and W_1-W_3 are independently CR^3;

R^3 is independently selected from hydrogen, (C_{1-6})alkoxy, and NH_2; and

R is independently selected from hydrogen, (C_{1-6})alkyl, $CONH_2$, COOH, hydroxy, halogen, and (C_{1-6})alkoxy.

38. (New) The compound according to claim 37 wherein R^4 and R^5 are independently selected from hydrogen, halo, hydroxy, (C_{1-4})alkoxy, trifluoromethoxy, nitro, cyano, aryl(C_{1-4})alkoxy and (C_{1-4})alkylsulphonyl; and R^6 is H or (C_{1-4})alkyl.

39. (New) The compound according to claim 37 wherein R^2 is a group:



;

wherein R^4 and R^5 are independently selected from hydrogen, halo, hydroxy, (C_{1-4})alkoxy, trifluoromethoxy, nitro, cyano, aryl(C_{1-4})alkoxy and (C_{1-4})alkylsulphonyl; and R^6 is hydrogen or (C_{1-4})alkyl.

40. (New) The compound according to claim 1 wherein:

Z_1, Z_2, Z_4 and Z_5 are each CH and Z_3 is CH or CF, or
Z_1 is N and Z_2, Z_3, Z_4 and Z_5 are each CH;

R^1 is methoxy or fluoro;

W_1-W_4 are independently CH; or
W_1, W_3 and W_4 are N and W_2 is CH; or
W_2 is N and W_1, W_3 and W_4 are independently CH; or
W_3 is N and W_1, W_2 and W_4 are independently CH; or
W_4 is N and W_1-W_3 are independently CH;

R is hydrogen;

R^2 is a group:



;

and R^4, R^5 and R^6 are hydrogen.

41. (New) A pharmaceutical composition comprising the compound according to claim 1 and a pharmaceutically acceptable carrier.

42. (New) A pharmaceutical composition comprising the compound according to claim 36 and a pharmaceutically acceptable carrier.

43. (New) A pharmaceutical composition comprising the compound according to claim 40 and a pharmaceutically acceptable carrier.